In the last trading session, 1.28 million Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) shares changed hands as the company’s beta touched 1.55. With the company’s per share price at $15.75 changed hands at $0.09 or 0.57% during last session, the market valuation stood at $2.07B. CNTA’s last price was a discount, traded about -21.21% off its 52-week high of $19.09. The share price had its 52-week low at $7.75, which suggests the last value was 50.79% up since then.
Analysts gave the Centessa Pharmaceuticals plc ADR (CNTA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended CNTA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Centessa Pharmaceuticals plc ADR’s EPS for the current quarter is expected to be -0.35.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Instantly CNTA was in green as seen at the end of in last trading. With action -3.14%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -5.97%, with the 5-day performance at -3.14% in the red. However, in the 30-day time frame, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is -4.31% down.
The consensus price target for the stock as assigned by Wall Street analysts is 23, meaning bulls need an upside of 31.52% from its current market value. According to analyst projections, CNTA’s forecast low is 19 with 28 as the target high. To hit the forecast high, the stock’s price needs a -77.78% plunge from its current level, while the stock would need to soar -20.63% for it to hit the projected low.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 6.85M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Centessa Pharmaceuticals plc ADR earnings to increase by 2.97%, but the outlook for the next 5-year period is at -3.20% per year.
CNTA Dividends
Centessa Pharmaceuticals plc ADR is expected to release its next quarterly earnings report in March.
GENERAL ATLANTIC, L.P. holds the second largest percentage of outstanding shares, with 8.8427% or 9.68 million shares worth $87.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund . With 2.98 shares estimated at $46.88 million under it, the former controlled 2.26% of total outstanding shares. On the other hand, Price (T.Rowe) Health Sciences Fund held about 2.24% of the shares, roughly 2.95 shares worth around $46.41 million.
